Primum Non Nocere: A Case of Valproate Encephalopathy

Basit Öğe Kaydı
dc.contributor.authorKozak, Hasan Huseyin
dc.contributor.authorUca, Ali Ulvi
dc.date.accessioned2024-02-23T14:41:35Z
dc.date.available2024-02-23T14:41:35Z
dc.date.issued2014
dc.departmentNEÜen_US
dc.description.abstractValproic acid (VPA) is a traditional antiepileptic which is used in the treatment of some types of epileptic seizures. Encephalopathy is a side effect of VPA which leads to rare but serious results and hyperammoniemia may be accompanied by one of these statements. It is specified that asymptomatic hyperammoniemia which VPA revealed is 20% and the incidence of symptomatic hyperammoniemia is 5%. The reason why VPA induced hyperammoniemia pathogenesis is not fully understood. In this article we present a 60-year-old male patient who was diagnosed VPA induced encephalopathy. The case presented is the first in the literature, in that, the patient previously taking valproate and whose encephalopathy unmonitored, valproate has been used after repeated seizures; and, after that encephalopathy has emerged.en_US
dc.identifier.doi10.5505/epilepsi.2014.84755
dc.identifier.endpage101en_US
dc.identifier.issn1300-7157
dc.identifier.issue2en_US
dc.identifier.startpage98en_US
dc.identifier.urihttps://doi.org/10.5505/epilepsi.2014.84755
dc.identifier.urihttps://hdl.handle.net/20.500.12452/16913
dc.identifier.volume20en_US
dc.identifier.wosWOS:000408851900009en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isotren_US
dc.publisherKare Publen_US
dc.relation.ispartofEpilepsien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEncephalopathyen_US
dc.subjectHyperammoniemiaen_US
dc.subjectValproic Aciden_US
dc.titlePrimum Non Nocere: A Case of Valproate Encephalopathyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu